New stem cell treatment may offer hope for Parkinson’s disease

Keck Medicine of USC investigates a unique therapy that aims to repair damaged brain cells

2026-02-05

(Press-News.org) LOS ANGELES — Parkinson’s disease is a progressive neurodegenerative disorder that affects more than one million people in the United States, with approximately 90,000 new cases diagnosed each year. Although available treatments can help manage symptoms, there is currently no cure or therapy proven to slow the progression of the disease.

Parkinson’s disease is associated with reduced dopamine release in the brain. Dopamine is a neurotransmitter essential for movement, memory, mood and other functions. Research has shown that the tremors, stiffness, slow movement and other symptoms of Parkinson’s disease are caused by the progressive loss of dopamine-producing brain cells, disrupting the brain’s ability to regulate movement.

Keck Medicine of USC is conducting an early phase clinical trial investigating the safety and effectiveness of implanting specialized stem cells into the brain that have been programmed to replace damaged brain cells and produce dopamine.

“If the brain can once again produce normal levels of dopamine, Parkinson’s disease may be slowed down and motor function restored,” said Brian Lee, MD, PhD, a neurosurgeon with Keck Medicine and principal investigator of the study.

Click here for seven warning signs of Parkinson’s disease

Unique stem cell therapy

The therapy is a relatively new type of lab-generated stem cell called induced pluripotent stem cells (iPSCs). Unlike embryonic stem cells, iPCSs are adult cells, such as skin or blood cells, reprogrammed to a "blank slate" state capable of evolving into any type of cell.

“We believe that these iPSCs can reliably mature into dopamine-producing brain cells, and offer the best chance of jump-starting the brain’s dopamine production,” said Xenos Mason, MD, a neurologist who specializes in Parkinson’s disease and other movement disorders with Keck Medicine and co-principal investigator of the study.

During the procedure, Lee drills a small hole in the patient’s skull to access the brain, then precisely implants the stem cells into the basal ganglia, a part of the brain that controls movement, under the guidance of magnetic resonance imaging (MRI).

After surgery, patients are monitored for 12-15 months for any changes in their Parkinson’s disease symptoms and for possible side effects including dyskinesia — excess movements — or infection. The doctors will continue to monitor the patients and their Parkinson’s disease symptoms for up to five years.

“Our ultimate goal is to pioneer a technique that can repair patients’ motor function and offer them a better quality of life,” said Lee.

Keck Medicine is one of three organizations in the United States participating in the clinical trial. The multisite study includes a total of 12 participants with moderate to moderate-severe Parkinson’s disease.

This announcement is intended to share information about Keck Medicine’s research involvement and is not soliciting participants.

###

For more information about Keck Medicine of USC, please visit news.KeckMedicine.org.

The stem cell product, RNDP-001, is manufactured by Kenai Therapeutics, a clinical-stage biotechnology company pioneering cures for neurological conditions. The U.S. Food & Drug Administration has granted the clinical trial, Phase 1 REPLACE™, fast-track designation, meaning that the development and review of the drug will be accelerated.

Disclosure: Mason has received an honorarium payment from Kenai Therapeutics in the past.

END

ELSE PRESS RELEASES FROM THIS DATE:

Researchers find new way to slow memory loss in Alzheimer’s

2026-02-05

Alzheimer’s disease is often measured in statistics: millions affected worldwide, cases rising sharply, costs climbing into the trillions. For families, the disease is experienced far more intimately. “It’s a slow bereavement,” says Cold Spring Harbor Laboratory Professor Nicholas Tonks, whose mother lived with Alzheimer’s. “You lose the person piece by piece.” There’s a lot of discussion about how the neurodegenerative disorder may be caused by a buildup of “plaque” ...

Insilico Medicine nominates ISM5059, the peripheral-restricted NLRP3 inhibitor as preclinical candidate

2026-02-05

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike ISM8969, Insilico’s brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency. Empowered by AI, ISM5059 demonstrated robust efficacy, excellent safety profiles in preclinical ...

Low-temperature-activated deployment of smart 4D-printed vascular stents

2026-02-05

Cardiovascular diseases constitute a major global health concern. Various complications that affect normal blood flow in arteries and veins, such as stroke, blood clot formation in veins, blood vessel rupture, and coronary artery disease, often require vascular treatments. However, existing vascular stent devices often require complex, invasive deployment procedures, making it necessary to explore novel materials and manufacturing technologies that could enable such medical devices to work more naturally with the human body. Moreover, the development of ...

Clinical relevance of brain functional connectome uniqueness in major depressive disorder

2026-02-05

Major depressive disorder (MDD) is a debilitating condition that affects more than 246 million people worldwide, yet scientists have struggled to identify consistent brain markers that could improve diagnosis and treatment. Finding reliable neurobiological markers for MDD has been hampered by the methodological differences observed across neuroimaging studies. Traditional brain imaging studies have produced conflicting results, often due to differences in methods and analysis pipelines. This inconsistency has made it difficult to pinpoint reliable neurobiological signatures of depression. Against this backdrop, a new study led by Research Fellow Siti Nurul Zhahara ...

For dementia patients, easy access to experts may help the most

2026-02-05

For Dementia Patients, Easy Access to Experts May Help the Most Programs that match caregivers with patient navigators yield better outcomes than Alzheimer’sdrug – but combining the two may be best. A Medicare-covered program that offers support and medical advice for caregivers of patients with dementia may bring more benefit than a costly Alzheimer’s medication, new research finds. UC San Francisco researchers compared outcomes for patients in collaborative care programs with those taking lecanemab, one of two approved drugs that have been shown to slow progression of Alzheimer’s in some patients. UCSF ...

YouTubers love wildlife, but commenters aren't calling for conservation action

2026-02-05

YouTube is a great place to find all sorts of wildlife content. It is not, however, a good place to find viewers encouraging each other to preserve that wildlife, according to new research led by the University of Michigan. Out of nearly 25,000 comments posted to more than 1,750 wildlife YouTube videos, just 2% featured a call to action that would help conservation efforts, according to a new study published in the journal Communications Sustainability. "Our results basically show that people like to watch videos of zoos and safaris and ...

New study: Immune cells linked to Epstein-Barr virus may play a role in MS

2026-02-05

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple sclerosis (MS), a chronic autoimmune disease that affects nearly one million Americans. The study, published Feb. 5 in Nature Immunology, found that certain types of CD8+ “killer” T cells — immune cells that destroy damaged or infected cells — are more abundant in people with MS. Some of these killer T cells target EBV, which suggests that the virus may trigger the damaging immune ...

AI tool predicts brain age, cancer survival, and other disease signals from unlabeled brain MRIs

2026-02-05

Mass General Brigham investigators have developed a robust new artificial intelligence (AI) foundation model that is capable of analyzing brain MRI datasets to perform numerous medical tasks, including identifying brain age, predicting dementia risk, detecting brain tumor mutations and predicting brain cancer survival. The tool. known as BrainIAC, outperformed other, more task-specific AI models and was especially efficient when limited training data were available. Results are published in Nature Neuroscience. “BrainIAC has ...

Peak mental sharpness could be like getting in an extra 40 minutes of work per day, study finds

2026-02-05

A new U of T Scarborough study finds that being mentally sharp can translate into a productivity boost equivalent to about 40 extra minutes of work each day. The study, published in the journal Science Advances, followed participants over a 12-week period and found that day-to-day fluctuations in mental sharpness helped explain why people sometimes fail to follow through on their goals. On days when participants were mentally sharp, they were more likely to set goals and complete them, whether it was finishing assignments or even just cooking ...

No association between COVID-vaccine and decrease in childbirth

2026-02-05

COVID-19 vaccination is not the cause behind a decrease in childbirth, according to a study from Linköping University, Sweden. The results speak against rumours about vaccination and reduced fertility. The findings have been published in the journal Communications Medicine. “Our conclusion is that it’s highly unlikely that the mRNA vaccine against COVID-19 was behind the decrease in childbirth during the pandemic,” says Toomas Timpka, professor of social medicine at Linköping ...

New stem cell treatment may offer hope for Parkinson’s disease

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: